Benesova, Iva
Capkova, Linda
Ozaniak, Andrej
Pacas, Pavel
Kopeckova, Katerina
Galova, Dominika
Lischke, Robert
Buchler, Tomas
Ozaniak Strizova, Zuzana
Funding for this research was provided by:
Grantová Agentura, Univerzita Karlova (GA UK No. 94323)
Ministerstvo Zdravotnictví Ceské Republiky (AZV NU23J-08-00031, AZV NU23J-08-00031, AZV NU23J-08-00031)
Univerzita Karlova v Praze (Cooperatio Program, Research Area SURG, Cooperatio Program, Research Area SURG)
Article History
Received: 17 December 2023
Accepted: 20 February 2024
First Online: 17 March 2024
Declarations
:
: Iva Benesova, Linda Capkova, Andrej Ozaniak, Pavel Pacas, Katerina Kopeckova, Dominika Galova, Robert Lischke, and Zuzana Ozaniak Strizova declare no conflict of interest. Tomas Buchler: Research support: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck KGaA, MSD, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi/Aventis; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol-Myers Squibb, AstraZeneca, Roche, Servier, Accord, MSD, and Pfizer. All unrelated to the present paper.
: This study was approved by the Ethics Committee for Multi-Centric Clinical Trials of the Motol University Hospital (Ref. EK-189/20) and was conducted in accordance with the Declaration of Helsinki of the World Medical Association.
: Due to the retrospective nature of the study, the acquisition of the informed consent was not required.
: Not applicable.